Rula Zain

9PUBLICATIONS
39CO-AUTHORS
Haematological tumoursMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Electrochemical energy storage and conversionApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Dec 26, 2025
T-cell immunomodulation occurs with different time kinetics during acalabrutinib and zanubrutinib therapy in chronic lymphocytic leukaemia.

Maria L Andersson, Olina Lind, Kia Heimersson

|Mar 26, 2024
Reduced clone size upon BTK inhibitor resistance mutations relates to toxicity caused by inherited PLCG2 gain-of-function variations.

C I Edvard Smith, Rula Zain

|Mar 20, 2024
In BTK, phosphorylated Y223 in the SH3 domain mirrors catalytic activity, but does not influence biological function.

H Yesid Estupiñán, Thibault Bouderlique, Chenfei He

|Oct 26, 2022
Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance.

Aishath Naeem, Filippo Utro, Qing Wang

|Nov 13, 2021
Growth Media Conditions Influence the Secretion Route and Release Levels of Engineered Extracellular Vesicles.

Jeremy P Bost, Osama Saher, Daniel Hagey

|Sep 26, 2021
Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients.

Lisa Blixt, Gordana Bogdanovic, Marcus Buggert

Pageof 2

Frequent Collaborators

8 joint publications

C I Edvard Smith

2 joint publications

H Yesid Estupiñán

2 joint publications

Anders Österborg

2 joint publications

Marzia Palma